von Willebrand Disease
Though von Willebrand Disease (VWD) is the most common inherited bleeding condition (affecting approximately 1% of the U.S. population), it is often misdiagnosed, particularly among women. Characterized by either quantitative, or qualitative defects of von Willebrand factor (VWF), a plasma protein that assists platelets as they initially adhere at sites of vascular injury, the correct diagnosis of variant VWD is essential to providing effective treatment. BloodCenter of Wisconsin, part of Versiti, is proud to offer one of the largest diagnostic menus to accurately and confidently diagnose VWD, and a streamlined reflexive algorithm for initial diagnosis.
Clear answers for your most complex VWD cases.
Our von Willebrand Disease testing algorithm uses a streamlined series of tests and analyses to correctly identify the disese variant in each patient. This unique appraoch to VWD management, with one clear order, can only be found through Versiti Blood Center of Wisconsin.
All Related Tests
1056
Anti-VWF Antibody IgG and IgM
This assay quantifies anti-VWF antibodies IgG and IgM using an ELISA plate method to support diagnosis of acquired von Willebrand disease.
1068
Ristocetin-Induced Platelet Aggregation (RIPA)
Aggregation with high and low dose ristocetin is used to identify patients with type 2B von Willebrand Disease, platelet-type von Willebrand Disease or Bernard-Soulier Syndrome. Citrated whole blood (light-blue top)
1800
VWD Diagnostic Evaluation
Reflexive algorithm always includes: FVIII Activity, VWF Antigen, VWF GPIbM Activity, and VWF Collagen III Binding. Reflex testing may include: VWD Type 2B Binding, VWD Type 2N Binding, VWF Propeptide Antigen, and/or VWF Quantitative Multimer
1289
VWD Platelet-Type Sequence Analysis
This test for platelet-type VWD provides sequencing of the full coding region (plus 30bp into the introns) of GPIBA.
1067
VWD Type 2B Evaluation
This order set includes VWD Type 2B Binding and VWD Type 2B Quantitative Multimer.
1089
VWD Type 2N Binding
This 2N-von Willebrand Disease panel is designed to distinguish type 2N-von Willebrand disease from mild hemophilia A and hemophilia A carriers.
1088
VWD Type 2N Profile
This order set includes: Factor VIII Activity, VWF Antigen and VWD Type 2N Binding.
1288
VWD Type 2N Sequence Analysis
Sequence analysis of VWF exons 17-21 and 24-27 detects germline variants associated with type 2N von willebrand disease (VWD).
1062
VWF Antigen
This assay measures a patient's total vWF protein level, independent of the multimer composition of the plasma
1279
VWF Collagen Binding Profile
This assay tests the capacity of platelet adhesion at sites of blood vessel injury and can identify qualitative binding issues. Includes VWF Antigen, VWF Collagen III Binding, and VWF Collagen IV Binding. Additional reflex to VWF Quantitative Multimer, if indicated.
1281
VWF Collagen III Binding
This assay tests the capacity of platelet adhesion at sites of blood vessel injury and can identify qualitative binding issues.
1280
VWF Collagen IV Binding
This assay tests the capacity of platelet adhesion at sites of blood vessel injury and can identify qualitative binding issues.
1284
VWF Exon 28 Sequence Analysis (For Type 2M or 2B VWD)
Sequence Analysis of VWF exon 28 detects germline variants associated with type 2B or type 2M von Willebrand disease (VWD).
1070
VWF GPIbM Activity
This ristocetin-independent activity assay is an alternative to VWF Ristocetin Cofactor Activity with superior precision and sensitivity.
1065
VWF Inhibitor Profile
This order set includes VWF Inhibitor Screen mixing study and VWF GPIbM Activity. If the VWF GPIbM result is >= 50 IU/dL, the inhibitor screen is invalid and will be cancelled and credited.
1282
VWF Propeptide Antigen
This assay evaluates propeptide antigen levels. This result should be correlated with VWF antigen, VWF ristocetin cofactor activity, VWF multimers, and clinical history by the ordering physician to arrive at the appropriate diagnosis.
1063
VWF Quantitative Multimer
Quantitative multimer analysis provides an objective measure of VWF structure to characterize subtle changes observed in the subtypes of VWD and may help to determine the nature of any additional clinical laboratory testing to reach a clear-cut diagnosis